Metformin may reduce food intake and body weight,but the anorexigenic effects of metformin are still poorly understood.In this study,Sprague-Dawley rats were administered a single intracerebroventricular dose of metformin and compound C,in a broader attempt to investigate the regulatory effects of metformin on food intake and to explore the possible mechanism.Results showed that central administration of metformin significantly reduced food intake and body weight gain,particularly after 4 hours.A reduction of neuropeptide Y expression and induction of AMP-activated protein kinase phosphorylation in the hypothalamus were also observed 4 hours after metformin administration,which could be reversed by compound C,a commonly-used antagonist of AMP-activated protein kinase.Furthermore,metformin also improved lipid metabolism by reducing plasma low-density lipoprotein.Our findings suggest that under normal physiologica conditions,central regulation of appetite by metformin is related to a decrease in neuropeptide Y gene expression,and that the activation of AMP-activated protein kinase may simply be a response to the anorexigenic effect of metformin. Metformin may reduce food intake and body weight, but the anorexigenic effects of metformin are still poorly understood. In this study, Sprague-Dawley rats were administered a single intracerebroventricular dose of metformin and compound C, in a broader attempt to investigate the regulatory effects of Metformin on food intake and to explore the possible mechanism. Results showed that central administration of metformin significant reduced food intake and body weight gain, particularly after 4 hours. A reduction of neuropeptide Y expression and induction of AMP-activated protein kinase phosphorylation in the hypothalamus were also observed 4 hours after metformin administration, which could be reversed by compound C, a commonly-used antagonist of Fusrthermore, metformin also improved lipid metabolism by reducing plasma low-density lipoprotein. Our findings suggest that under normal physiologica conditions, central regulation of appetite by metformin is related to a dec rease in neuropeptide Y gene expression, and that the activation of AMP-activated protein kinase may simply be a response to the anxixigenic effect of metformin.